Compare Ecolab Inc. (ECL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Sana Biotechnology Inc — how do they compare? Ecolab Inc. trades at $281.42 (market cap $78.97B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Ecolab Inc. is far larger — about 94.4× Sana Biotechnology Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Sana Biotechnology Inc for 23 Days on average.
| ECL | SANA | |
|---|---|---|
Market Cap | $78.97B | $836.71M |
Volume | 974,947 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $5.92 |
52-Week Low | $245.73 | $2.68 |
Typical Hold Time | 90 Days | 23 Days |
Enterprise Value | $87.75B | $749.96M |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $282.21, up 1.48% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $16.08B, net income of $2.08B, and a 12.57% net margin. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook is positive given earnings beats, dividend reliability, and strategic expansions like the CoolIT deal, though rising debt and cost pressures pose risks. With a consensus price target of $326.38 implying 16% upside, ECL offers growth potential but requires monitoring of leverage and execution.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
